IRONWOOD PHARMACEUTICALS, INC. (IRWD) Debt Components
- 2025-09-30: Long-term DebtUSD $199.51M; Long-Term Debt, Maturity, Year OneUSD $201.50M; Long-Term Debt, Maturity, Year TwoUSD (m); Long-Term Debt, Maturity, Remainder of Fiscal YearUSD $1.50M.
- 2025-06-30: Long-term DebtUSD $199.33M; Long-Term Debt, Maturity, Year OneUSD $201.50M; Long-Term Debt, Maturity, Year TwoUSD (m); Long-Term Debt, Maturity, Remainder of Fiscal YearUSD $1.50M.
- 2025-03-31: Long-term DebtUSD $199.16M; Long-Term Debt, Maturity, Year OneUSD $201.50M; Long-Term Debt, Maturity, Year TwoUSD (m); Long-Term Debt, Maturity, Remainder of Fiscal YearUSD $3.00M.
- 2024-12-31: Long-term DebtUSD $198.99M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m); Long-Term Debt, Maturity, Remainder of Fiscal YearUSD (m).
IRONWOOD PHARMACEUTICALS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Notes Payable, Current USD | Long-term Debt, Current Maturities USD | Convertible Notes Payable USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Debt Instrument, Fee Amount USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Convertible, Carrying Amount of Equity Component USD | Debt Instrument, Unamortized Discount USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | $199.51M | $201.50M | (m) | $1.50M | $203.00M | $200.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $199.33M | $201.50M | (m) | $1.50M | $203.00M | $200.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $199.16M | $201.50M | (m) | $3.00M | $204.50M | $200.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $198.99M | (m) | (m) | (m) | (m) | $200.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $198.82M | $3.00M | $201.50M | $1.50M | $206.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $198.65M | $3.00M | $201.50M | $1.50M | $206.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $398.28M | $3.00M | $201.50M | $203.75M | $408.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $397.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $397.46M | $203.75M | $3.00M | $2.25M | $410.50M | (m) | (m) | (m) | (m) | $201.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $397.06M | $203.75M | $3.00M | $2.25M | $410.50M | (m) | (m) | (m) | (m) | $201.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $396.65M | $203.75M | $3.00M | $4.50M | $412.75M | (m) | (m) | (m) | (m) | $201.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $396.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $4.50M | $203.75M | (m) | $412.75M | (m) | (m) | (m) | (m) | $3.00M | $201.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $395.85M | $4.50M | $203.75M | $2.25M | $415.00M | (m) | (m) | (m) | (m) | $3.00M | $201.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $395.45M | $4.50M | $203.75M | $2.25M | $415.00M | (m) | (m) | (m) | (m) | $3.00M | $201.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $515.63M | $4.50M | $203.75M | $126.56M | $539.31M | (m) | (m) | $120.70M | (m) | $3.00M | $201.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $454.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $112.31M | $61.64M |
| 2021-12-31 | (m) | $126.56M | $4.50M | (m) | $539.31M | (m) | (m) | (m) | (m) | $203.75M | $3.00M | $201.50M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $448.04M | $126.56M | $4.50M | $3.61M | $542.91M | (m) | (m) | $120.70M | (m) | $203.75M | $3.00M | $201.50M | (m) | (m) | (m) | $112.31M | $67.35M |
| 2021-06-30 | $442.01M | $126.56M | $4.50M | $3.61M | $542.91M | (m) | (m) | $120.70M | (m) | $203.75M | $3.00M | $201.50M | (m) | (m) | (m) | $112.31M | $72.96M |
| 2021-03-31 | $436.08M | $126.56M | $4.50M | $7.22M | $546.52M | (m) | (m) | (m) | (m) | $203.75M | $3.00M | $201.50M | (m) | (m) | (m) | $112.31M | $78.48M |
| 2020-12-31 | $430.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $112.31M | $83.90M |
| 2020-12-31 | (m) | $7.22M | $126.56M | (m) | $546.52M | (m) | (m) | (m) | (m) | $4.50M | $203.75M | $3.00M | $201.50M | (m) | (m) | (m) | (m) |
| 2020-09-30 | $424.54M | $7.22M | $126.56M | $3.61M | $550.13M | (m) | (m) | (m) | (m) | $4.50M | $203.75M | $3.00M | $201.50M | (m) | (m) | (m) | $89.23M |
| 2020-06-30 | $418.92M | $7.22M | $126.56M | $3.61M | $550.13M | (m) | (m) | (m) | (m) | $4.50M | $203.75M | $3.00M | (m) | (m) | (m) | (m) | $94.47M |
| 2020-03-31 | $413.41M | (m) | $7.22M | $7.22M | $553.74M | (m) | (m) | (m) | (m) | $126.56M | $4.50M | $203.75M | (m) | (m) | (m) | (m) | $99.63M |
| 2019-09-30 | $402.68M | (m) | $7.22M | $2.90M | $556.63M | (m) | (m) | (m) | (m) | $7.22M | $126.56M | $4.50M | (m) | (m) | (m) | (m) | $109.69M |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | $48.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | $45.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $47.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | $39.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | $24.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | $11.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-01-05 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.70M | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $234.24M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | $8.40M | (m) | $230.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | $35.26M | (m) | $227.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | $28.24M | (m) | $223.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $220.62M | (m) | (m) | (m) | $335.70M | (m) | $24.96M | (m) | $220.62M | (m) | (m) | (m) | (m) | (m) | (m) | $114.20M | $107.64M |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | $20.12M | (m) | $217.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $11.70M | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | $17.57M | (m) | $214.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | $13.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $11.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | $9.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | $6.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | $4.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |